Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

opella healthcare czech s.r.o., praha array - 19566 odtuČnĚnÉ sÓjovÉ fosfolipidy - tvrdá tobolka - 300mg - fosfolipidy

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

opella healthcare czech s.r.o., praha array - 19566 odtuČnĚnÉ sÓjovÉ fosfolipidy - tvrdá tobolka - 600mg - fosfolipidy

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

cheplapharm arzneimittel gmbh, greifswald array - 17806 suchÝ ČiŠtĚnÝ a standardizovanÝ ostropestŘecovÝ extrakt - potahovaná tableta - 70mg - silymarin

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

wörwag pharma gmbh & co. kg, böblingen array - 17806 suchÝ ČiŠtĚnÝ a standardizovanÝ ostropestŘecovÝ extrakt - obalená tableta - silymarin

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

viatris healthcare limited, dublin array - 13533 suchÝ ostropestŘecovÝ extrakt - tvrdá tobolka - 140mg - silymarin

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

viatris healthcare limited, dublin array - 13533 suchÝ ostropestŘecovÝ extrakt - tvrdá tobolka - 70mg - silymarin

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

stada arzneimittel ag, bad vilbel array - 17806 suchÝ ČiŠtĚnÝ a standardizovanÝ ostropestŘecovÝ extrakt - obalená tableta - 50mg - silymarin

Česká republika - čeština - USKVBL (Ústav Pro Státní Kontrolu Veterinárních Biopreparátů A Léčiv)

fatro, s.p.a. - játra terapie - injekční roztok - jÁtra terapie, lipotropics - koně, kozy, prasata, skot, psi

Evropská unie - čeština - EMA (European Medicines Agency)

mylan ireland limited - rivaroxaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - antitrombotické činidla - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers.  rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.  ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.  treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Evropská unie - čeština - EMA (European Medicines Agency)

accord healthcare s.l.u. - rivaroxaban - acute coronary syndrome; coronary artery disease; peripheral arterial disease; venous thromboembolism; stroke; atrial fibrillation; pulmonary embolism - antitrombotické činidla - prevence žilní tromboembolie (vte) u dospělých pacientů, kteří podstoupili elektivní operaci náhrady kyčelního nebo kolenního kloubu. léčba hluboké žilní trombózy (dvt) a plicní embolie (pe) a prevence rekurentní dvt a pe u dospělých. (see section 4. 4 for haemodynamically unstable pe patients. léčba hluboké žilní trombózy (dvt) a plicní embolie (pe) a prevence rekurentní dvt a pe u dospělých. (see section 4. 4 pro hemodynamicky nestabilní pe pacientů). adultsprevention of stroke and systemic embolism in adult patients with non valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. léčba hluboké žilní trombózy (dvt) a plicní embolie (pe) a prevence rekurentní dvt a pe u dospělých. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. rivaroxaban accord, co administered with acetylsalicylic acid (asa) alone or with asa plus ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers (see sections 4. 3, 4. 4 a 5. rivaroxaban accord, co administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. léčba hluboké žilní trombózy (dvt) a plicní embolie (pe) a prevence rekurentní dvt a pe u dospělých. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.